COVID-19 Vaccine Education at the Point of Testing to Increase Vaccine Uptake in Vulnerable Communities in SE Louisiana
NCT04939506 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 379
Last updated 2024-02-23
Summary
This project is a 2-year study to investigate vaccine hesitancy and vaccine completion among vulnerable communities in the Southeastern Louisiana region. This study will be used to track COVID-19 vaccine completion among patients who seek testing, either as in-person or purchasing at home COVID testing, from pharmacies, urgent cares and clinics using a rapid vaccine education model delivered at the point of care.
Conditions
- Covid19
- Vaccine Refusal
- Vaccine Hesitancy
Interventions
- BEHAVIORAL
-
COVID-19 Vaccine Education at the Point of COVID-19 Testing
A rapid vaccination education model to be delivered at the point of COVID-19 testing by pharmacy students, pharmacy technicians, nurse's aides and other health care personnel. The intervention will include: 1) 15 minute vaccine counseling, 2) print material 3) referral to a dedicated vaccine website with feedback forums and 4) opportunity to sign-up for one-on-one vaccine counseling with a clinical pharmacist
Sponsors & Collaborators
-
Xavier University of Louisiana.
lead OTHER
Principal Investigators
-
Sara Al-Dahir, PharmD · Xavier University of Louisiana.
-
Klaus Heyer, PhD · Nunez Community College
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-09-01
- Primary Completion
- 2023-11-30
- Completion
- 2024-01-25
Countries
- United States
Study Locations
More Related Trials
-
Message Encouraging Vaccination in Preparation for the Holidays
NCT05612360 ·Status: COMPLETED ·Phase: NA
-
Prevenar (PCV-7) Post-Licensure Safety Study In Russia
NCT01207583 ·Status: COMPLETED
-
Testing the Persuasiveness of Pro-inoculation Arguments
NCT05804825 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
NCT00744263 ·Status: COMPLETED ·Phase: PHASE4
-
Improving Pneumococcal Vaccination Rates in an Ambulatory Pre-surgical Testing Setting
NCT01787838 ·Status: COMPLETED ·Phase: NA
-
P3+ Intervention Phase
NCT02898688 ·Status: COMPLETED ·Phase: NA
-
Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.
NCT01026038 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Prevenar Immunogenicity in High Risk Children
NCT00581620 ·Status: COMPLETED ·Phase: PHASE4
-
Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age
NCT07348692 ·Status: RECRUITING ·Phase: PHASE3
-
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
NCT04398706 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
NCT05489328 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico
NCT00708682 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
NCT02116998 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine
NCT00624819 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Immunogeneicity of Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults
NCT03549208 ·Status: UNKNOWN ·Phase: PHASE1
-
Study Evaluating Prevenar in High-Risk Children
NCT00234338 ·Status: COMPLETED
-
COVID-19 Reactogenicity
NCT07051031 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Vaccination Coverage and Level of Protection in Patients at Risk
NCT03820752 ·Status: COMPLETED
-
Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center
NCT01944462 ·Status: COMPLETED ·Phase: PHASE4
-
13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico
NCT01432262 ·Status: COMPLETED ·Phase: PHASE3
-
Post-Marketing Study of the Safety of Prevenar (Pneumococcal Conjugate Vaccine, 7-valent)
NCT00683410 ·Status: COMPLETED
-
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
NCT00384059 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults
NCT06182124 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV
NCT05163834 ·Status: COMPLETED ·Phase: PHASE1